1 |
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross- sectional survey [J]. Lancet, 2012, 379(9818): 815-822.
|
2 |
Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end- stage renal disease: 25- year follow- up [J]. Arch Intern Med, 2009, 169(4): 342-350.
|
3 |
Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease [J]. J Am Soc Nephrol, 2008, 19(12): 2407-2413.
|
4 |
Kim WJ, Kim SS, Bae MJ, et al. High- normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function [J]. J Diabetes Complications, 2014, 28(2): 130-134.
|
5 |
Liu YL, Pan Y, Wang X, et al. Betaine reduces serum uric acid levels and improves kidney function in hyperuricemic mice [J]. Planta Med, 2014, 80(1): 39-47.
|
6 |
Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes [J]. J Diabetes Complications, 2014, 28(2): 124-129.
|
7 |
Prasad SO, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review [J]. Nephrourol Mon, 2015, 7(3): e27233.
|
8 |
Wang S, Chen R, Liu Q, et al. Prevalence, awareness and treatment of chronic kidney disease among middle- aged and elderly: the China health and retirement longitudinal study [J]. Nephrology (Carlton), 2015, 20(7): 474-484.
|
9 |
Yang B, Mo Z, Wu C, et al. A genome- wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population [J]. BMC Med Genomics, 2014, 7: 10.
|
10 |
Mallamaci F, Testa A, Leonardis D, et al. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family- based study [J]. Am J Kidney Dis, 2015, 65(2): 294-302.
|
11 |
Kumral E, Karaman B, Orman M, et al. Association of uric acid and carotid artery disease in patients with ischemic stroke [J]. Acta Neurol Scand, 2014, 130(1): 11-17.
|
12 |
唐湘玲,陈梦颖,张卫茹. 慢性肾脏病患者血清内脏脂肪素水平升高及其与颈动脉粥样硬化的关系[J].中南大学学报(医学版), 2013,38(6): 554-559.
|
13 |
Bao X, Wang Q, Chen G, et al. Serum concentration of uric acid associated with prehypertension among Chinese population [J]. Angiology, 2014, 65(9): 800-805.
|
14 |
Liu YL, Pan Y, Wang X, et al. Betaine reduces serum uric acid levels and improves kidney function in hyperuricemic mice [J]. Planta Med, 2014, 80(1): 39-47.
|
15 |
Cai G, Zheng Y, Sun X, et al. Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of prevalence, awareness, and treatment rates in chronic kidney disease patients with hypertension in China [J]. J Am Geriatr Soc, 2013, 61(12): 2160-2167.
|
16 |
中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J]. 中华内分泌代谢杂志,2013,29(11): 913-920.
|
17 |
Hamburger M, Baraf HS, Adamson TR, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia [J]. Phys Sportsmed, 2011, 39(4): 98-123.
|
18 |
Soltani Z, Rasheed K, Kapusta DR, et al. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal [J]? Curr Hypertens Rep, 2013, 15(3): 175-181.
|
19 |
Qiu L, Cheng XQ, Wu J, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces [J]. BMC Public Health, 2013, 13: 664.
|
20 |
Xue C, Ye XD, Li W, et al. Prevalence of chronic kidney disease in Jing adults in China: a village- based study [J]. Clin Nephrol, 2013, 79(1): 50-56.
|
21 |
Goicoechea M, Garcia DVS, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long- term follow- up of a randomized clinical trial [J]. Am J Kidney Dis, 2015, 65(4): 543-549.
|
22 |
Bellomo G. The relationship between uric acid, allopurinol, cardiovascular events, and kidney disease progression: a step forward [J]. Am J Kidney Dis, 2015, 65(4): 525-527.
|
23 |
Park DJ, Kang JH, Lee JW, et al. Cost- effectiveness analysis of HLA- B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea [J]. Arthritis Care Res (Hoboken), 2015, 67(2): 280-287.
|
24 |
Sakai Y, Otsuka T, Ohno D, et al. Febuxostat for treating allopurinol- resistant hyperuricemia in patients with chronic kidney disease [J]. Ren Fail, 2014, 36(2): 225-231.
|
25 |
Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease [J]. J Clin Pharm Ther, 2013, 38(3): 258-261.
|
26 |
Ohno I. The cutting- edge of medicine; role of hyperuricemia in cardiorenal syndrome [J]. Nihon Naika Gakkai Zasshi, 2013, 102(6): 1484-1491.
|
27 |
Yood RA, Ottery FD, Irish W, et al. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo- controlled, phase 3 clinical trials [J]. BMC Res Notes, 2014, 7: 54.
|
28 |
Bleyer AJ, Wright D, Alcorn H. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end- stage renal failure receiving hemodialysis [J]. Clin Nephrol, 2015, 83(5): 286-292.
|